American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Sarepta shares fall 37% as FDA questions future of key gene therapy

by admin July 19, 2025
July 19, 2025
Sarepta shares fall 37% as FDA questions future of key gene therapy

Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration is considering whether to halt the distribution of Elevidys, the company’s flagship gene therapy for Duchenne Muscular Dystrophy (DMD).

The move comes amid an ongoing investigation into multiple patient deaths tied to Sarepta’s gene therapy programs.

A source familiar with the matter told CNBC that the FDA is preparing to request Sarepta voluntarily suspend shipments of Elevidys, though the agency has yet to formally contact the company.

Sarepta said it had not received any direct communication from the FDA as of Friday.

Separately, FDA Commissioner Marty Makary confirmed to Bloomberg News that the agency is reviewing whether Elevidys should remain on the market, raising fears that Sarepta’s primary commercial product could be withdrawn entirely.

Deaths reignite long-standing safety concerns

The FDA’s concerns follow the deaths of two teenage boys from liver failure earlier this year after receiving Elevidys.

A third patient, enrolled in a Phase 1 trial for a different Sarepta gene therapy, also died recently.

While the therapies differ in their targets, both use the same delivery mechanism, fueling broader safety concerns.

Elevidys has been controversial from the outset.

Initially granted conditional approval in 2023 for DMD patients aged 4 to 5 who could still walk, its approval was expanded in 2024 to include all ambulatory patients aged 4 and up, and conditionally for non-ambulatory patients.

The latter decision drew criticism, as clinical data showed weaker evidence of efficacy in this group.

Further concerns arose when Elevidys failed to meet its primary goal in a Phase 3 trial.

Nevertheless, former FDA official Peter Marks sided with Sarepta, citing secondary benefits in the trial to justify expanded approval, a move that has since come under renewed scrutiny.

Baird downgrades Sarepta stock; analysts warn of dire consequences if Elevidys approval revoked

The regulatory probe has dealt a blow to Sarepta, which relies heavily on Elevidys for its revenue.

The therapy accounted for more than half of Sarepta’s total net product revenue.

With the company’s shares now down more than 87% year-to-date, investors are bracing for the possibility that the FDA may revoke approval altogether.

Analyst Kostas Biliouris of BMO Capital Markets noted that while other gene therapies, such as Novartis’s Zolgensma, have also faced safety issues, the clear benefit of Zolgensma justifies the risk.

“That’s why deaths here matter so much versus Zolgensma, for example,” Biliouris said.

The company has stopped shipping Elevidys to non-ambulatory patients while it assesses alternative delivery methods.

Still, Sarepta executives insist the drug could bring in $500 million annually even if limited to treating ambulatory patients.

The company’s future now hinges on the FDA’s decision. “If the FDA pulls Elevidys from the market,” Biliouris warned, “Sarepta is done.”

“Although the development of SRP-9004 has been discontinued, we believe the death could lead to greater scrutiny of SRP-9003’s safety profile ahead of its BLA submission and could affect commercial interest, if approved,” brokerage William Blair said.

Baird downgraded Sarepta Therapeutics to Neutral from Outperform, with a $15 Price Target.

The post Sarepta shares fall 37% as FDA questions future of key gene therapy appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition
next post
Donald Trump demands 15-20% tariffs on EU: report

Related Posts

Boohoo and THG Group shares have imploded: buy...

September 25, 2024

What can we expect in 2025? Ipsos survey...

December 25, 2024

N.Y. Fed President John Williams says inflation is...

June 2, 2024

Firefly Aerospace surges over 50% in Nasdaq debut,...

August 8, 2025

S&P 500, Dow rise on strong US jobs...

October 5, 2024

Why Costco stock slipped post-Q4: 3 reasons, plus...

September 27, 2025

S&P 500, Nasdaq close at all-time highs ahead...

July 11, 2024

Pernod Ricard shares climb as sales, profit beat...

August 28, 2025

RGTI, QSI, QMCO, IONQ stocks are surging: time...

December 27, 2024

SBI shares rise as Q1 profit beats estimates;...

August 11, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Europe bulletin: Manchester synagogue attack aftermath, stocks close higher

      October 5, 2025
    • Evening digest: Trump sets deadline for Hamas, Canada’s slowdown, BTC rebounds

      October 5, 2025
    • Iran executes six people for alleged links to Israel, state media reports

      October 5, 2025
    • US digest: Trump’s Hamas ultimatum, government shutdown stalemate continues

      October 5, 2025
    • Japanese stocks may extend record run as Takaichi win revives ‘Abenomics’

      October 5, 2025

    Categories

    • Business (4,191)
    • Investing (2,958)
    • Latest News (2,080)
    • Politics (1,536)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved